| T cell-mediated Immune response and correlates of inflammation and their relationship with COVID-19 clinical severity: not an intuitive guess NM Pena, LC Santana, JR Hunter, VF Blum, T Vergara, C Gouvea, E Leal, ... BMC Infectious Diseases 24 (1), 612, 2024 | | 2024 |
| Impact of interrupting antiretroviral therapy started during primary HIV-1 infection on plasma neurofilament light chain protein, a marker of neuronal injury: The SPARTAC trial J Alagaratnam, W Stöhr, E Hamlyn, K Porter, J Toombs, A Heslegrave, ... Journal of Virus Eradication 10 (2), 100381, 2024 | | 2024 |
| RE: Post-exposure prophylaxis-in-pocket for HIV prevention M Schechter | | 2024 |
| Could well-established, widely available, and simple laboratory techniques explain a laboratory origin of SARS-CoV-2? RM Lloyd Jr, JR Hunter, RS Diaz, M Schechter Brazilian Journal of Infectious Diseases 27 (5), 102808, 2023 | 1 | 2023 |
| Dolutegravir-associated resistance mutations after first-line treatment failure in Brazil RS Diaz, JR Hunter, M Camargo, D Dias, J Galinskas, I Nassar, ... BMC Infectious Diseases 23 (1), 347, 2023 | 14 | 2023 |
| T Cell-mediated Immune Response and Correlates of Inflammation and their relationship with COVID-19 clinical severity: not an intuitive guess. N Mantovani, L Santana, J Hunter, V Blum, T Vergara, C Gouvea, E Leal, ... | | 2023 |
| Mpox in people with advanced HIV infection: a global case series O Mitjà, A Alemany, M Marks, JIL Mora, JC Rodríguez-Aldama, MST Silva, ... The Lancet 401 (10380), 939-949, 2023 | 242 | 2023 |
| Geographical differences in the self-reported functional impairment of people with human immunodeficiency virus (HIV) and associations with cardiometabolic risk KM Erlandson, KV Fitch, SA McCallum, HJ Ribaudo, ET Overton, ... Clinical Infectious Diseases 75 (7), 1154-1163, 2022 | 3 | 2022 |
| Effects of Carbon Nanomaterials and Aloe vera on Melanomas—Where Are We? Recent Updates EN de Carvalho Lima, GL Barros Martins, RS Diaz, M Schechter, ... Pharmaceutics 14 (10), 2004, 2022 | 3 | 2022 |
| COVID-19 Clinical Severity, T Cell-Mediated Immune Response, and Correlates of Inflammation: Not an Intuitive Guess NM Pena, LC Santana, JR Hunter, VF Blum, TRC Vergara, JDS Ferraz, ... SPARC Working, COVID-19 Clinical Severity, T Cell-Mediated Immune Response …, 2022 | | 2022 |
| Pre-Exposure Prophylaxis Failure With a Multiple Drug-Resistant HIV-1 Clade C Virus in Brazil RS Diaz, A Grangeiro, DL Estevam, J Galinskas, D Dias, M Schechter JAIDS Journal of Acquired Immune Deficiency Syndromes 89 (2), e16, 2022 | | 2022 |
| Effects of Carbon Nanomaterials and Aloe vera on Melanomas—Where Are We? Recent Updates. Pharmaceutics 2022, 14, 2004 EN de Carvalho Lima, GL Barros Martins, RS Diaz, M Schechter, ... s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2022 | | 2022 |
| High transmitted drug resistance in Brazil: unprecedented levels of INSTI resistance DB Caldeira, TRC Vergara, ELB d Santos, CAF Lopes, CRB Alves, ... Journal of the International AIDS Society. Oxford, 2022 | | 2022 |
| Geographical differences in the self-reported functional impairment of people with HIV and associations with cardiometabolic risk KM Erlandson, KV Fitch, SA McCallum, HJ Ribaudo, ET Overton, M Zanni, ... Clin Infect Dis, 2022 | 4 | 2022 |
| Broadly neutralizing antibody responses in the longitudinal primary HIV-1 infection Short Pulse Anti-Retroviral Therapy at Seroconversion cohort LA Granger, I Huettner, F Debeljak, P Kaleebu, M Schechter, G Tambussi, ... AIDS 35 (13), 2073-2084, 2021 | 1 | 2021 |
| Broadly neutralizing antibody responses in the longitudinal primary HIV-1 infection SPARTAC cohort LA Granger, I Huettner, F Debeljak, P Kaleebu, M Schechter, G Tambussi, ... AIDS, 2021 | | 2021 |
| Is France once again looking for a scapegoat? MM Lederman, JS Flier, P Hale, AT Haase, W Powderly, P Reiss, ... Pathogens and Immunity 6 (2), 149, 2021 | 1 | 2021 |
| Nota sobre o uso da cloroquina/hidroxicloroquina para o tratamento da COVID-19 CF Ramos Filho, CT Daniel-Ribeiro, DG Tabak, DC Baia-da-Silva, ... ENSP/Fiocruz, 2020 | 5 | 2020 |
| Evaluating the impact of policies recommending PrEP to subpopulations of men and transgender women who have sex with men based on demographic and behavioral risk factors H Janes, MD Brown, DV Glidden, KH Mayer, SP Buchbinder, ... Plos one 14 (9), e0222183, 2019 | 2 | 2019 |
| Impact of estimated pre-exposure prophylaxis (PrEP) adherence patterns on bone mineral density in a large PrEP demonstration project MA Spinelli, DV Glidden, PL Anderson, M Gandhi, VM McMahan, ... AIDS research and human retroviruses 35 (9), 788-793, 2019 | 18 | 2019 |
Lee H. HarrisonCenter for Genomic Epidemiology, University of Pittsburgh在 edc.pitt.edu 的电子邮件经过验证
